⌘K

AVTX

NASDAQ

Avalo Therapeutics Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2015

News25/Ratings12

News · 26 weeks68+38%

2025-10-262026-04-19

Mix4490d

Insider19(43%)
Other15(34%)
SEC Filings7(16%)
Analyst3(7%)

Latest news

25 items

13dSEC
SEC Form DEFA14A filed by Avalo Therapeutics Inc.
DEFA14A - Avalo Therapeutics, Inc. (0001534120) (Filer)
13dSEC
SEC Form DEF 14A filed by Avalo Therapeutics Inc.
DEF 14A - Avalo Therapeutics, Inc. (0001534120) (Filer)
14dANALYST
Wolfe Research initiated coverage on Avalo Therapeutics with a new price target
Wolfe Research initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $48.00
15dINSIDER
SEC Form 4 filed by Doyle Mittie
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
17dANALYST
Citizens initiated coverage on Avalo Therapeutics with a new price target
Citizens initiated coverage of Avalo Therapeutics with a rating of Mkt Outperform and set a new price target of $52.00
20dINSIDER
SEC Form 4 filed by Sullivan Christopher Ryan
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
20dINSIDER
SEC Form 4 filed by Doyle Mittie
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
22dSEC
SEC Form 144 filed by Avalo Therapeutics Inc.
144 - Avalo Therapeutics, Inc. (0001534120) (Subject)
22dINSIDER
SEC Form 4 filed by Jain Rita
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
22dINSIDER
SEC Form 4 filed by Lind Kevin Robert
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
22dSEC
SEC Form SCHEDULE 13G filed by Avalo Therapeutics Inc.
SCHEDULE 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)
23dINSIDER
SEC Form 4 filed by Truex Samantha
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
23dINSIDER
SEC Form 4 filed by Kantoff Aaron
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
23dINSIDER
SEC Form 4 filed by Kaplan Gilla
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
23dINSIDER
SEC Form 4 filed by Neil Garry Arthur
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
23dINSIDER
SEC Form 4 filed by Sullivan Christopher Ryan
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
23dINSIDER
SEC Form 4 filed by Chan Mitchell
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
23dINSIDER
SEC Form 4 filed by Goldman Jonathan
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
27dSEC
Avalo Therapeutics Inc. filed SEC Form 8-K: Leadership Update
8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
31dSEC
SEC Form S-8 filed by Avalo Therapeutics Inc.
S-8 - Avalo Therapeutics, Inc. (0001534120) (Filer)
31dSEC
SEC Form 10-K filed by Avalo Therapeutics Inc.
10-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
31dSEC
Avalo Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
31dPR
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
Topline data expected from Phase 2 LOTUS trial of abdakibart (AVTX-009) for the treatment of hidradenitis suppurativa in the second quarter of 2026Cash, cash equivalents and short-term investments of approximately $98 million as of December 31, 2025 expected to provide runway into 2028 WAYNE, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) ("Avalo"), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced business updates and year-end financial results for 2025. "2025 was a year of disciplined execution focused on the LOTUS trial, and we are thrilled to be approac
36dINSIDER
SEC Form 4 filed by Doyle Mittie
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
48dSEC
SEC Form SCHEDULE 13G filed by Avalo Therapeutics Inc.
SCHEDULE 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)